ArticleNature structural & molecular biology2020
Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.
Open access · bronzeAbstract read
In one paragraph
Article in Nature structural & molecular biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 233 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
233citing papers in PubMed, 1 pooled it
10.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
233 citing papers in PubMed, 1 synthesis or guideline pooled it, 460 citations in OpenAlex.
- Pooled it
- Lipid tail length dictates membrane disruption by carmofur analogs and reveals noncanonical modes of action.RSC advances · 2026Article
- Identification of Potential SARS-CoV-2 Main Protease (MPro) Inhibitors Through Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Simulation Approaches.International journal of molecular sciences · 2026Article
- SARS-CoV-2 3CLpro inhibits the replication of influenza viruses through the cleavage of NP and PA.Virologica Sinica · 2026Article
- Drug Repurposing as a Broad-Spectrum Strategy Against Coronaviruses: Frontiers in Mechanisms and Clinical Translation.Viruses · 2026Review
- A Novel Covalent Inhibitor Fragment for the SARS-CoV-2 Main Protease Identified by Target-Specific Deep Learning.ACS chemical biology · 2026Article
- Study of Structural, Vibrational, and Molecular Docking Properties of (1Molecules (Basel, Switzerland) · 2026Article
- Targeting SARS-CoV-2 main protease for the discovery of a broad-spectrum COVID-19 inhibitor by intensive multi-tiered validation.Acta pharmaceutica Sinica. B · 2025Article
- Azapeptide-Based SARS-CoV-2 Main Protease Inhibitors: Design, Synthesis, Enzyme Inhibition, Structural Determination, and Antiviral Activity.Journal of medicinal chemistry · 2025Article
- Reproducibility of QM/MM Calculations for the SARS-CoV-2 Main Protease.Journal of chemical theory and computation · 2025Article
- Carmofur Exhibits Antimicrobial Activity AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Research Progress on the Structure and Function, Immune Escape Mechanism, Antiviral Drug Development Methods, and Clinical Use of SARS-CoV-2 MMolecules (Basel, Switzerland) · 2025Review
- Design, Synthesis and Biological Exploration of NovelInternational journal of molecular sciences · 2024Article
- Two-step tandem synthesis of sugar-containing pyrimidine derivatives catalyzed by Lipozyme® TL IM in continuous-flow microreactors.RSC advances · 2024Article
- Allostery in homodimeric SARS-CoV-2 main protease.Communications biology · 2024Article
- Taming the storm: potential anti-inflammatory compounds targeting SARS-CoV-2 MPro.Inflammopharmacology · 2024Review
- 3-chymotrypsin-like protease in SARS-CoV-2.Bioscience reports · 2024Review
- Boosting immunity: synergistic antiviral effects of luteolin, vitamin C, magnesium and zinc against SARS-CoV-2 3CLpro.Bioscience reports · 2024Article
- Development of a new experimental NMR strategy for covalent cysteine protease inhibitors screening: toward enhanced drug discovery.RSC advances · 2024Article
- Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.Antiviral research · 2024Article
173 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
21 authors at 6 institutions in 3 countries.
Zhenming Jin *Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.ORCID http://orcid.org/0000-0001-6448-820X
Yao Zhao *Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Yuan Sun *State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.ORCID http://orcid.org/0000-0001-8244-7436
Bing ZhangShanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Haofeng WangShanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Yan WuState Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Yan ZhuShanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Chen ZhuShanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Tianyu HuShanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Xiaoyu DuShanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.ORCID http://orcid.org/0000-0002-8415-8686
Yinkai DuanShanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Jing YuShanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Xiaobao YangShanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Xiuna YangShanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Kailin YangTaussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
Xiang LiuState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Response, College of Life Sciences, College of Pharmacy, Nankai University, Tianjin, China.ORCID http://orcid.org/0000-0001-5498-6942
Luke W GuddatSchool of Chemistry and Molecular Biosciences, the University of Queensland, Brisbane, Australia.
Gengfu XiaoState Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Leike ZhangState Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China. zhangleike@wh.iov.cn.ORCID http://orcid.org/0000-0002-2593-2571
Haitao YangShanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China. yanght@shanghaitech.edu.cn.ORCID http://orcid.org/0000-0002-1875-3268
Zihe RaoShanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
ShanghaiTech University · CNChinese Academy of Sciences · CNNankai University · CNCleveland Clinic · USThe University of Queensland · AUTianjin University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antineoplastic drug carmofur is shown to inhibit the SARS-CoV-2 main protease (M
Indexed as
AnimalsBetacoronavirusChlorocebus aethiopsCoronavirus 3C ProteasesCoronavirus InfectionsCOVID-19Cysteine EndopeptidasesFluorouracilModels, MolecularPandemicsPneumonia, ViralSARS-CoV-2Vero CellsViral Nonstructural ProteinscarmofurCoronavirus 3C ProteasesCysteine EndopeptidasesFluorouracilViral Nonstructural Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.